Wed, Oct 1, 2014, 3:39 PM EDT - U.S. Markets close in 21 mins.

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • atpl1959 atpl1959 Jun 25, 2013 12:42 PM Flag

    In Elderly HL

    patients survival statistics are not good. Almost 25% of EHL patients treated with ABVD suffered treatment related death. 32% of EHL patients treated with ABVD sufered Bleomycin lung toxicity.
    So what's a little pancreatitis compared with the alternative ABVD regimen. Not too make light of pancreatitis but I'll bet it is much more related to the AVD and the poor shape these EHL patients are in, than the Adcetris itself. I'm more interested in the clinical trial of Adcetris alone in treating EHL patients. Haven't heard of that one being stopped.
    I wonder if Adam Fuerstein had anything to do with that bearish options bet.
    Let's wait on the facts

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think investors just don't follow or understand their investments. To sell SGEN based on safety fears is as unfounded as it can get. Of all the reasons to sell that would be the last IMO. There has never been a less toxic way to deliver chemo IMO. For those that know this is an opportunity.

    • Now why could the company PR bozos just come out and officially put things in perspective just like you just did. You know it and many if not most of us know it but it is still painfull to watch your investment shrink especially in a day that should have been a huge up day due to the additional validation of the technology by Bayer.
      Why is an accomplished technology and management team allowing A. Fuerstein to dictate the company's PR and even claiming that the company knowingly and willfully lied about a minor event that can be easily dispelled with fact based reasons?
      This guy is hardly qualified to flush a toilet but so far has been allowed to blunt today's really good news.

 
SGEN
36.775-0.405(-1.09%)3:39 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.